These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1839532)

  • 41. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment.
    Brennscheidt U; Brunnmüller U; Proppe D; Thomann P; Seiler KU
    Arzneimittelforschung; 2007; 57(2):106-11. PubMed ID: 17396621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose and species dependent pharmacokinetics of a novel sigma receptor antagonist, DuP 734.
    Kapil RP; Lam GN
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):3-20. PubMed ID: 7620836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.
    van der Lee MJ; Blenke AA; Rongen GA; Verwey-van Wissen CP; Koopmans PP; Pharo C; Burger DM
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4098-104. PubMed ID: 17846135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The disposition and metabolism of (+)-cyanidanol-3 in patients with alcoholic cirrhosis.
    Smillie MV; Griffiths LA; Male PJ; Wermeille MM
    Eur J Clin Pharmacol; 1987; 33(3):255-9. PubMed ID: 3691613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.
    Stenderup J; Eriksen J; Pedersen SB; Christiansen LV
    Eur J Clin Pharmacol; 1985; 28(5):573-9. PubMed ID: 3876221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical pharmacology of paroxetine in healthy subjects.
    Raptopoulos P; McClelland GR; Jackson D
    Acta Psychiatr Scand Suppl; 1989; 350():46-8. PubMed ID: 2530788
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacokinetics and safety of deramciclane during multiple oral dosing.
    Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absorption of paroxetine under various dietary conditions and following antacid intake.
    Greb WH; Brett MA; Buscher G; Dierdorf HD; von Schrader HW; Wolf D; Mellows G; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():99-101. PubMed ID: 2530802
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.
    Hall KW; Nightingale CH; Gibaldi M; Nelson E; Bates TR; DiSanto AR
    J Clin Pharmacol; 1982 Jul; 22(7):321-5. PubMed ID: 7107981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regional distribution of serotonergic pre- and postsynaptic markers in human brain.
    Laruelle M; Maloteaux JM
    Acta Psychiatr Scand Suppl; 1989; 350():56-9. PubMed ID: 2530792
    [No Abstract]   [Full Text] [Related]  

  • 52. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection.
    Brett MA; Dierdorf HD; Zussman BD; Coates PE
    J Chromatogr; 1987 Aug; 419():438-44. PubMed ID: 2959675
    [No Abstract]   [Full Text] [Related]  

  • 53. An interim overview of the safety and tolerability of paroxetine.
    Dunbar GC
    Acta Psychiatr Scand Suppl; 1989; 350():135-7. PubMed ID: 2530767
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver.
    Pentikäinen PJ; Neuvonen PJ; Jostell KG
    Eur J Clin Pharmacol; 1980 Apr; 17(4):275-84. PubMed ID: 6995129
    [No Abstract]   [Full Text] [Related]  

  • 55. Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients.
    De Deyn PP; Van de Velde V; Verslegers W; Saerens J; Pickut BA; Clincke B; Woestenborghs R; Van Peer A
    Eur J Clin Pharmacol; 1992; 43(6):661-2. PubMed ID: 1493851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers.
    Vermerie N; Kusielewicz D; Tod M; Nicolas P; Perret G; Fauvelle F; Petitjean O
    Fundam Clin Pharmacol; 1992; 6(4-5):197-203. PubMed ID: 1358775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.
    Jochemsen R; Van Beusekom BR; Spoelstra P; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1983 Mar; 15(3):295-302. PubMed ID: 6849765
    [No Abstract]   [Full Text] [Related]  

  • 58. The metabolism of zinc and selenium in cirrhotic patients during six weeks of zinc ingestion.
    Sullivan JF; Williams RV; Burch RE
    Alcohol Clin Exp Res; 1979 Jul; 3(3):235-9. PubMed ID: 384833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On the impact of the metabolic state in cirrhotic patients.
    Müller MJ
    Nutrition; 1997; 13(7-8):687-8. PubMed ID: 9263261
    [No Abstract]   [Full Text] [Related]  

  • 60. Potential medication interactions with paroxetine use for cough in cancer patients.
    Wong AB; Hui L; Hong J
    J Oncol Pharm Pract; 2020 Jul; 26(5):1296. PubMed ID: 32279597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.